Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesLiabilities and Shareholders EquityPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Groove Botanicals (GRVE) Cash & Equivalents (2016 - 2025)

Groove Botanicals' Cash & Equivalents history spans 8 years, with the latest figure at $104574.0 for Q1 2017.

  • On a quarterly basis, Cash & Equivalents fell 3.37% to $104574.0 in Q1 2017 year-over-year; TTM through Mar 2017 was $104574.0, a 3.37% decrease, with the full-year FY2017 number at $104574.0, down 3.37% from a year prior.
  • Cash & Equivalents hit $104574.0 in Q1 2017 for Groove Botanicals, down from $126854.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for GRVE hit a ceiling of $321160.0 in Q2 2013 and a floor of $104574.0 in Q1 2017.
  • Historically, Cash & Equivalents has averaged $148332.1 across 5 years, with a median of $129931.0 in 2013.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 185.02% in 2013 and later plummeted 58.26% in 2014.
  • Tracing GRVE's Cash & Equivalents over 5 years: stood at $111365.0 in 2013, then increased by 6.18% to $118249.0 in 2014, then rose by 14.57% to $135477.0 in 2015, then decreased by 6.36% to $126854.0 in 2016, then fell by 17.56% to $104574.0 in 2017.
  • Business Quant data shows Cash & Equivalents for GRVE at $104574.0 in Q1 2017, $126854.0 in Q4 2016, and $106697.0 in Q3 2016.